BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122	NDA	AstraZeneca Pharmaceuticals LP	0310-4616-12	120 AEROSOL, METERED in 1 INHALER (0310-4616-12)	2020-07-23
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122	NDA	AstraZeneca Pharmaceuticals LP	0310-4616-28	28 AEROSOL, METERED in 1 INHALER (0310-4616-28)	2020-07-23
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122	NDA	AstraZeneca Pharmaceuticals LP	0310-4616-39	28 AEROSOL, METERED in 1 INHALER (0310-4616-39)	2020-07-23
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 28, 2025

Introduction

The pharmaceuticals BUDESONIDE, FORMOTEROL FUMARATE, and GLYCOPYRROLATE play critical roles in managing respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Securing reliable suppliers is essential for pharmaceutical manufacturers, distributors, and healthcare providers to ensure consistent drug supply, regulatory compliance, and patient safety. This article offers an in-depth analysis of the major suppliers for these drugs, considering manufacturing, regional distribution, and market trends.

Budesonide: Overview and Key Suppliers

Budesonide is an inhaled corticosteroid primarily used for asthma and allergic rhinitis management. Its pharmacological profile requires specialized formulation and delivery mechanisms, involving complex manufacturing processes maintained by established pharmaceutical companies.

Major Suppliers

AstraZeneca
- Role: Patent holder and primary manufacturer of Budesonide inhalers and formulations.
- Products: Pulmicort (budesonide inhaler), Rhinocort Aqua nasal spray.
- Market Presence: Global leader with extensive distribution networks, especially strong in North America, Europe, and emerging markets.
- Manufacturing Sites: Multiple facilities across Europe and North America, adhering to stringent cGMP standards.
Teva Pharmaceutical Industries
- Role: Licensed manufacturer and distributor of generic Budesonide formulations.
- Products: Generic inhalers and nasal sprays.
- Market Position: Largest generic drug manufacturer globally, with high-volume supply to cost-sensitive markets.
Mylan (Part of Viatris)
- Role: Supplies generic versions of Budesonide, primarily for inhalation and nasal formulations.
- Market Focus: Expanding access in lower-income countries with cost-effective generics.
Sandoz (Novartis)
- Role: Produces biosimilar and generic formulations of Budesonide.
- Distribution: Widely available across Europe and select emerging Asian markets.

Regional and Contract Manufacturers
Numerous regional pharmaceutical manufacturers in India, China, and Eastern Europe produce both branded and generic Budesonide under licensing agreements or through local manufacturing licenses, expanding the supply network.

Formoterol Fumarate: Overview and Key Suppliers

Formoterol Fumarate is a long-acting beta-agonist (LABA) used in combination with inhaled corticosteroids or alone for maintenance therapy in asthma and COPD. Its chemical complexity necessitates specialized synthetic pathways.

Major Suppliers

AstraZeneca
- Role: Co-developer and primary manufacturer of Formoterol-containing products such as Symbicort (with Budesonide).
- Market Penetration: Strong presence in European and North American markets with extensive licensing agreements.
Mylan/Viatris
- Role: Manufactures generic Formoterol Fumarate inhalers.
- Market Scope: Focused on developing markets, offering cost-efficient alternatives.
Teva
- Role: Supplies generic Formoterol for inhalation therapy in various markets.
- Distribution Network: Global, covering North America, Europe, and Asia.
Sun Pharmaceutical Industries
- Role: Indian origin company manufacturing Formoterol generics.
- Strategy: Targets Asian and African markets with affordable options.
Other Regional Manufacturers
- Multiple Chinese and Eastern European companies produce Formoterol under licensing or as unbranded generics, contributing to supply diversification.

Research and Development
Emerging biopharmaceutical firms are exploring aerosolized forms with extended-release profiles to improve delivery and adherence, potentially altering market dynamics in the future.

Glycopyrrolate: Overview and Key Suppliers

Glycopyrrolate is an anticholinergic agent for inhalation, primarily used as a bronchodilator in COPD management. It is also marketed in parenteral forms for preoperative applications.

Major Suppliers

Sun Pharmaceutical Industries / Cipla
- Role: Market Leader in India and Asia for inhaled Glycopyrrolate.
- Product Portfolio: Multiple formulations including nebulized and metered-dose inhalers (MDIs).
Mylan/Viatris
- Role: Produces generic Glycopyrrolate inhalation products for both domestic and international markets.
- Market Focus: Expanding availability in the U.S. and European markets.
Glenmark Pharmaceuticals
- Role: Indian-based company manufacturing Glycopyrrolate inhalers.
- Distribution: Focused on Asian and African markets.
AstraZeneca
- Role: Developed and marketed the branded Glycopyrrolate inhalation therapy named Seebri Neohaler.
- Market Share: Significant in developed markets with patent-protected formulations.
Other Generics Manufacturers
- Several Chinese pharmaceutical firms produce unbranded or licensed Glycopyrrolate inhalers, augmenting global supply chains.

Regulatory and Patent Landscape

The patent expiration of branded Glycopyrrolate formulations has spurred multiple generics, heightening supply competition. Regulatory approvals vary, with key markets requiring strict bioequivalence and safety data submission.

Market Trends and Supply Chain Considerations

Geographical shifts in supply sources are driven by manufacturing cost advantages, regulatory environments, and local demand. Indian and Chinese firms have become pivotal players, especially for generic versions, due to their robust manufacturing infrastructure and cost advantages.

Supply chain resilience now increasingly depends on securing diversified sources to mitigate risks such as geopolitical tensions, regulatory hurdles, and manufacturing disruptions, especially amid the COVID-19 pandemic's impact.

Regulatory compliance remains paramount. Suppliers must maintain adherence to cGMP standards, obtain necessary approvals from agencies like the FDA, EMA, and other regional authorities, and align with drug patent laws.

Innovation and biosimilars are emerging trends, especially for complex molecules like Budesonide, which may influence future supplier strategies through licensing agreements and new formulations.

Regulatory and Qualification Aspects

Manufacturers intending to secure or expand supply chains should prioritize compliance with international standards and seek verified approvals from global regulating agencies. Engaging with Contract Manufacturing Organizations (CMOs) with proven track records can facilitate regulatory approvals and quality assurance.

Key Challenges in Supplier Selection

Quality Assurance: Ensuring suppliers meet strict cGMP and bioequivalence standards.
Cost Considerations: Balancing affordability with quality, especially in emerging markets.
Intellectual Property Rights: Navigating patent landscapes and licensing agreements.
Supply Chain Stability: Managing risks related to geopolitical issues and logistics.
Regulatory Approvals: Securing necessary registrations for regional markets.

Key Takeaways

Diverse Supplier Base: The global supply of Budesonide, Formoterol Fumarate, and Glycopyrrolate relies on a mix of patent-holders, generics manufacturers, and regional producers, providing flexibility but requiring vigilant quality checks.
Leading Patent Holders and Innovators: AstraZeneca, as a primary innovator for Budesonide and Formoterol, maintains significant control over branded formulations, while Indian and Chinese firms dominate the generic segment.
Emerging Trends: Growth in biosimilars, extended-release formulations, and combination therapies will influence future supplier needs and market competition.
Regulatory Vigilance: Maintaining compliance with evolving international regulatory standards remains crucial for sustaining supply and avoiding disruptions.
Market Dynamics: Cost pressures and patent expirations fuel increased generic competition, notably in emerging markets, affecting supplier choices and pricing strategies.

FAQs

1. Who are the dominant global suppliers of Budesonide?
AstraZeneca remains the dominant patent holder and manufacturer, with several generic producers such as Teva, Mylan, and Sandoz playing key roles in supplying affordable alternatives worldwide.

2. How does regional manufacturing impact supply stability?
Regional manufacturers in India and China significantly expand supply capacity, especially for generics, but require rigorous quality assurance and regulatory compliance to ensure drug safety.

3. Are biosimilars a future consideration for these drugs?
While biosimilars typically relate to biologics, ongoing research into novel delivery systems and formulations may lead to biosimilar-like competition, particularly for complex molecules such as Budesonide.

4. What factors influence supplier choice for pharmaceutical companies?
Quality compliance, cost-effectiveness, regulatory approvals, supply reliability, and licensing agreements are primary factors influencing supplier selection.

5. How have patent expirations affected the supply landscape?
Patent expirations have encouraged widespread generic manufacturing, increasing supply sources but also necessitating careful quality monitoring and regulatory adherence to ensure safety and efficacy.

Sources

[1] AstraZeneca Annual Reports and Product Information.
[2] Teva Pharmaceuticals drug portfolio.
[3] Mylan's official product listings.
[4] Sandoz and Novartis official communications.
[5] Regulatory filings and approvals for Glycopyrrolate (FDA, EMA, etc.).

This comprehensive analysis aims to guide pharmaceutical stakeholders in sourcing and supply chain planning for Budesonide, Formoterol Fumarate, and Glycopyrrolate, facilitating informed decision-making rooted in market realities.

Suppliers and packagers for generic pharmaceutical drug: BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE